公开(公告)号：US11992558B2

公开(公告)日：2024-05-28

申请号：US17261858

申请日：2019-07-21

申请人： Sushma Paul Berlia

发明人： Sushma Paul Berlia ,  Nishant Berlia ,  Anupama Diwan ,  Sunder Singh Bhandari

IPC分类号： A61K9/20 ,  A61J3/10 ,  A61K9/00 ,  A61K9/28 ,  A61K31/453

CPC分类号： A61K9/2077 ,  A61J3/10 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2853 ,  A61K9/2893 ,  A61K31/453

摘要： The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.

公开(公告)号：US11826472B2

公开(公告)日：2023-11-28

申请号：US18143927

申请日：2023-05-05

申请人： PURDUE PHARMA L.P. ,  PURDUE PHARMACEUTICALS L.P.

发明人： William H. McKenna ,  Richard O. Mannion ,  Edward P. O'Donnell ,  Haiyong H. Huang

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K9/16 ,  A61J3/06 ,  A61K9/00 ,  A61K31/485 ,  A61K47/34 ,  A61K9/24 ,  A61K45/06 ,  A61K47/10 ,  A61J3/10 ,  B29C43/00 ,  A61J3/00 ,  B29C37/00 ,  B29C43/52 ,  B29B7/88 ,  B29C35/04 ,  B29B7/02 ,  B29C35/16 ,  B29C43/02 ,  B29C71/00 ,  B29K71/00 ,  B29K105/00 ,  B29L31/00

CPC分类号： A61K9/28 ,  A61J3/005 ,  A61J3/06 ,  A61J3/10 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/1641 ,  A61K9/209 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/284 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K31/485 ,  A61K45/06 ,  A61K47/10 ,  A61K47/34 ,  B29B7/02 ,  B29B7/88 ,  B29C35/045 ,  B29C35/16 ,  B29C37/0025 ,  B29C43/003 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29C71/009 ,  A61K9/2072 ,  B29C2035/046 ,  B29C2035/1658 ,  B29K2071/02 ,  B29K2105/0035 ,  B29K2105/251 ,  B29K2995/0088 ,  B29L2031/753

摘要： The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

公开(公告)号：US20230233410A1

公开(公告)日：2023-07-27

申请号：US17999925

申请日：2021-05-25

申请人： Perfetti Van Melle S.P.A.

发明人： Güven Marangoz ,  Joaquin Antonio Lizano Iglesias ,  Alessandro Bottini

IPC分类号： A61J3/10 ,  B30B11/08 ,  B30B11/34 ,  A61K9/20

CPC分类号： A61J3/10 ,  B30B11/08 ,  B30B11/34 ,  A61K9/2095

摘要： A process is disclosed for the manufacture of a compressed product consisting of a multilayer tablet formed in a single compression operation.

公开(公告)号：US20230172949A1

公开(公告)日：2023-06-08

申请号：US17814567

申请日：2022-07-25

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  AustinPx, LLC

发明人： Chris BROUGH ,  James W. MCGINITY ,  Dave A. MILLER ,  James C. DINUNZIO ,  Robert O. WILLIAMS, III

IPC分类号： A61K31/573 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61J3/00 ,  A61J3/07 ,  A61J3/10 ,  A61K31/343 ,  A61K31/496 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K31/573 ,  A61K9/146 ,  A61K9/1694 ,  A61K9/2077 ,  A61J3/00 ,  A61J3/07 ,  A61J3/10 ,  A61K31/343 ,  A61K31/496 ,  A61K47/32 ,  A61K47/38

摘要： Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

公开(公告)号：US20230097809A1

公开(公告)日：2023-03-30

申请号：US18061680

申请日：2022-12-05

申请人： Altria Client Services LLC

发明人： Feng GAO ,  Frank Scott ATCHLEY ,  Gregory James GRISCIK ,  Christopher Joseph DINOVI ,  Phillip M. HULAN ,  Diane L. GEE ,  Jason FLORA ,  Shuzhong ZHUANG

IPC分类号： A61K31/465 ,  B29C48/00 ,  A24B15/14 ,  A24B15/16 ,  A24B15/30 ,  A61J3/10 ,  A61K9/00 ,  A61K9/20 ,  A61K36/81 ,  A61K45/06

摘要： An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.

公开(公告)号：US11517566B2

公开(公告)日：2022-12-06

申请号：US16942014

申请日：2020-07-29

申请人： Altria Client Services LLC

发明人： Feng Gao ,  Frank Scott Atchley ,  Gregory James Griscik ,  Christopher Joseph Dinovi ,  Phillip M. Hulan ,  Diane L. Gee ,  Jason Flora ,  Shuzhong Zhuang

IPC分类号： A24B15/14 ,  A61K31/465 ,  B29C48/00 ,  A24B15/16 ,  A24B15/30 ,  A61J3/10 ,  A61K9/00 ,  A61K9/20 ,  A61K36/81 ,  A61K45/06 ,  B29K75/00 ,  B29K401/00 ,  B29K407/00 ,  B29L31/00

摘要： An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.

公开(公告)号：US20220354797A1

公开(公告)日：2022-11-10

申请号：US17174764

申请日：2021-02-12

申请人： Vertex Pharmaceuticals Incorporated

发明人： Marinus Jacobus Verwijs

IPC分类号： A61K9/28 ,  A61K31/443 ,  A61K45/06 ,  A61J3/10 ,  A61K9/16 ,  A61K9/20 ,  A61K31/47 ,  A61K31/4709

摘要： A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.

公开(公告)号：US20220347102A1

公开(公告)日：2022-11-03

申请号：US17765934

申请日：2020-10-01

申请人： Synthon B.V.

发明人： Sara FRADERA GELABERT ,  Lisardo ALVAREZ FERNANDEZ ,  Rohit KUMAR

IPC分类号： A61K9/20 ,  A61K31/4166 ,  A61J3/10 ,  A61J3/00

摘要： The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.

公开(公告)号：US20220331305A1

公开(公告)日：2022-10-20

申请号：US17853537

申请日：2022-06-29

申请人： Novartis AG

发明人： Michaela Anna Maria Bock ,  Frantz Elbaz ,  Charu Kochhar ,  Doris Stingelin

IPC分类号： A61K31/4439 ,  A61K9/20 ,  A61K31/454 ,  A61K9/00 ,  A61J3/10 ,  A61K9/10

摘要： The present invention relates to dispersible tablets comprising the compound (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-I, I-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceuti-cally acceptable salt thereof.

公开(公告)号：US20220265517A1

公开(公告)日：2022-08-25

申请号：US17625150

申请日：2020-07-21

申请人： I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A.

发明人： Massimo RIBANI ,  Maurizio BEDETTI ,  Alessandro MASOTTI

IPC分类号： A61J3/07 ,  A23P10/30 ,  A61K9/48 ,  B65B63/02 ,  A61J3/10 ,  B65B1/26

摘要： A filling machine (1) includes a dosing station (3) comprising a supporting element (5) and a dosing unit (10) having a dosing cylinder (12) and a piston (13), for filling bodies (101) of capsule (100) with a product (P) picked-up from a tank (4); the supporting element (5) is movable between a lowered picking position (B), in which the dosing unit (10) is inserted in the tank (4) and a dosing position (C) in which the dosing unit (10) faces a body (101); the piston (13) is movable between a first internal position (D) to form a dosing chamber (15) suitable for picking up and retaining a dose (PI) of product (P), a second internal position (E) to reduce a volume of the dosing chamber (15) and compress the dose (PI) and an external position (F) to push the dose (PI) from the dosing cylinder (12) into a body (101).